Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy

Deng, Le; Xu, Gaosi

doi:10.1007/s40265-023-01855-y

Cited by 9 publications

(7 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to consider hypokalemia as a potential complication during RTX therapy. Although RTX has shown effectiveness in treating various medical conditions (Deng and Xu, 2023), it is important to consider the risk of hypokalemia. Vigilant monitoring of potassium levels, prompt intervention when necessary, and appropriate potassium replacement are vital to ensure the safe and successful management of patients receiving RTX therapy.…”

Section: Discussionmentioning

confidence: 99%

Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia

Zhang,

Sun,

Gao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Rituximab (RTX) is a monoclonal antibody commonly used to treat PLA2R-associated membranous nephropathy (MN). This report presents a case of refractory MN in a patient who experienced severe hypokalemia, a rare but clinically significant condition, after the 5th RTX infusion. Clinicians should be aware of the potential for hypokalemia and its management during or after RTX infusion. After the onset of hypokalemia, the patient received treatment with obinutuzumab and achieved partial remission of renal disease without experiencing further hypokalemia. Obinutuzumab may be a viable alternative therapy for refractory membranous nephropathy that develops side effects after rituximab therapy or is refractory to it, but further studies are necessary to determine its efficacy and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia

Zhang,

Sun,

Gao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…With the expanding utilization of rituximab in the management of MN, the treatment failure of rituximab prompted various speculations, such as concerns about anti-rituximab antibody development, rituximab underdosing because of urinary excretion, and incomplete depletion of B-cells in lymphoid organs. 13 , 14 …”

Section: Discussionmentioning

confidence: 99%

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series

Lin,

Han,

Chen

et al. 2024

Kidney Medicine

View full text Add to dashboard Cite

“… 170 While rituximab is deemed safe and efficacious for patients with MN, 171 , 172 there are limitations to its effectiveness as 20–40% of patients do not respond. 173 This lack of response may be attributed to higher PLA2R antibody titers, thus necessitating the exploration of alternative therapies with enhanced efficacy. Over the past decade, two new drugs, Obinutuzumab 174 , 175 and Belimumab, 176 , 177 have been discovered.…”

Section: Treatment Strategies For Mnmentioning

confidence: 99%

Membranous nephropathy: pathogenesis and treatments

Wang,

Yang,

Fang

et al. 2024

MedComm

View full text Add to dashboard Cite

Membranous nephropathy (MN), an autoimmune disease, can manifest at any age and is among the most common causes of nephrotic syndrome in adults. In 80% of cases, the specific etiology of MN remains unknown, while the remaining cases are linked to drug use or underlying conditions like systemic lupus erythematosus, hepatitis B virus, or malignancy. Although about one‐third of patients may achieve spontaneous complete or partial remission with conservative management, another third face an elevated risk of disease progression, potentially leading to end‐stage renal disease within 10 years. The identification of phospholipase A2 receptor as the primary target antigen in MN has brought about a significant shift in disease management and monitoring. This review explores recent advancements in the pathophysiology of MN, encompassing pathogenesis, clinical presentations, diagnostic criteria, treatment options, and prognosis, with a focus on emerging developments in pathogenesis and therapeutic strategies aimed at halting disease progression. By synthesizing the latest research findings and clinical insights, this review seeks to contribute to the ongoing efforts to enhance our understanding and management of this challenging autoimmune disorder.

show abstract

Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy

Cited by 9 publications

References 177 publications

Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia

Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series

Membranous nephropathy: pathogenesis and treatments

Contact Info

Product

Resources

About